Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 outpatients meta-analysis

BLAZE-1 phase 2 (monotherapy)
RCTbamlanivimab monotherapyplaceboCOVID 19 outpatientssome concern
101/156 inconclusive
    no significant difference in viral load reduction was observed for bamlanivimab monotherapy at any dose
    1 study excluded by filtering options (0 RCT / 1 OBS)

    PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
    Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).